Blue Label impairs Cell C investment to nil for year end, is it time to buy?


With both Net1 & Blue Label impairing their Cell C investment to nil for their year ends, CNBC Africa’s Fifi Peters asked Henry Biddlecombe, an Analyst at Anchor Capital, whether he would be buying Blue Label?